Can a Chlamydia Test Be Wrong? False Positives & Negatives

Modern chlamydia tests are highly accurate, but they can produce both false positives and false negatives. The most widely used tests today, known as nucleic acid amplification tests (NAATs), generally catch well over 95% of true infections and correctly rule out chlamydia in over 99% of uninfected people. That still leaves room for error, though, and the reasons a result might be wrong range from biological quirks to simple timing.

How Accurate Are Today’s Chlamydia Tests

Most chlamydia testing in clinics and labs uses NAATs, which work by detecting and amplifying tiny amounts of chlamydia’s genetic material. These tests represent a massive improvement over older methods. Head-to-head comparisons of different NAATs have found sensitivities for chlamydia ranging from about 94% to 100%, with specificities of 98% to 100%, depending on the specific platform and specimen type.¹ One evaluation of the Cepheid GeneXpert rapid PCR test, for example, found chlamydia sensitivity between 97.4% and 98.7% across different specimen types, with specificity at 99.4% or higher in both women and men.²

Those numbers sound reassuring, and they largely are. But a sensitivity of 97% still means roughly 3 out of 100 infected people will get a negative result. And even a specificity of 99.5% means that in a population where chlamydia is uncommon, a surprising share of positive results could be false alarms. The practical accuracy of any test depends not just on the test itself but on who is being tested, when, and how.

Why a Negative Result Might Be Wrong

False negatives are more common than false positives with modern NAATs, and the most frequent culprit is timing. Chlamydia has an incubation period, and if you test too soon after exposure, the bacterial load may be too low for even a sensitive test to pick up. Most guidelines suggest waiting at least one to two weeks after a potential exposure before testing, though some infections may take longer to reach detectable levels.

Sample collection also matters. A systematic review and meta-analysis comparing self-collected and clinician-collected specimens found that self-collected vaginal swabs had a sensitivity of about 92% and specificity of about 98% for chlamydia when compared against clinician-collected cervical swabs.³ Self-collection works well in most cases, but an improperly collected specimen, whether it’s a swab that barely touches the right area or a urine sample collected at the wrong time, can reduce accuracy. For urine-based tests, the standard recommendation is to use the first part of the urine stream and to avoid urinating for at least one to two hours before collection. Ignoring those instructions can dilute the sample enough to produce a false negative.

Low bacterial load is another factor. Some infections, particularly those that are asymptomatic and have been present for a while, carry relatively little bacterial DNA. NAATs are the best available option for catching these low-level infections, especially in populations like children where asymptomatic, low-load infections are a particular diagnostic challenge.⁴

The Anatomic Site Problem

One of the most underappreciated causes of false negatives is testing the wrong body site. Standard screening in many settings involves a genital swab or urine test. But chlamydia can also infect the rectum and the throat, and infections at those sites are often completely asymptomatic. A study examining screening practices found that over 80% of rectal and pharyngeal chlamydia cases among cisgender men would be missed if only urogenital testing was performed.⁵

This is not a failure of the test itself. The NAAT would detect chlamydia at those sites if a sample were taken from there. The problem is that clinicians and patients often do not think to test the rectum or throat unless the patient explicitly reports anal or oral sexual contact. Even then, some people may not volunteer that information. If you have reason to think you may have been exposed at an extragenital site, ask specifically for testing at that location. A negative urine test does not rule out a rectal or throat infection.

Genetic Variants That Dodge Detection

A more unusual cause of false negatives has emerged in recent years. Certain strains of chlamydia carry mutations in the genetic regions that some NAATs are designed to detect, allowing those strains to partially or fully escape detection. Researchers in England identified two chlamydia variants carrying mutations in the 23S rRNA target region used by the Aptima Combo 2 assay, one of the most commonly used NAAT platforms worldwide.⁶

These diagnostic escape variants have since been found in Nordic countries, Japan, the United States, and Canada. A Canadian surveillance study conducted between 2019 and 2021 found that about 5% of specimens flagged for discrepant results carried mutations allowing them to escape Aptima Combo 2 detection.⁷ Researchers have also detected a diagnostic-avoidant variant carrying a G1523A mutation in cervical and endometrial specimens identified during unrelated microbiome research, underscoring how these variants can lurk in tested populations without triggering standard assays.⁸

The good news is that these variants are still relatively rare in the broader population, and many labs use confirmatory protocols that can catch discrepant results. But the phenomenon is a reminder that no single test platform is permanently foolproof, and ongoing surveillance matters.

Why a Positive Result Might Be Wrong

False positives with modern NAATs are uncommon, but they do happen, and the most important cause is something many people find counterintuitive: the test can detect chlamydia DNA or RNA that is no longer from a living infection. After successful antibiotic treatment, dead chlamydia organisms shed their genetic material, and NAATs can pick up those remnants for days or even weeks. One study found that in over a third of vaginal swab samples, less than 1% of the chlamydia DNA detected came from viable organisms, meaning the vast majority of what the test was finding was already dead bacteria in the process of being cleared.⁹ Researchers have noted that these “blips” of genetic material can result from degrading cells, nonviable genetic fragments deposited by a sexual partner, or remnants of the original infection still being expelled by the body.¹⁰

This is why the CDC recommends against retesting too soon after treatment. Retesting in the first few weeks after antibiotics can produce a positive result that looks like treatment failure or reinfection but is actually just leftover DNA. For non-pregnant patients, guidelines suggest retesting between about 60 and 183 days after treatment, while pregnant patients have a shorter retesting window of roughly 21 to 42 days.¹¹ Testing within that recommended window helps distinguish a genuine new infection from residual genetic noise.

Cross-Reactivity With Older Test Formats

If you have been tested using a method other than a NAAT, the false-positive picture changes significantly. Older antigen-detection tests like the Chlamydiazyme assay (an enzyme immunoassay) were notorious for cross-reacting with other bacteria. One study tested over 1,000 clinical isolates and found that about 6% of gram-negative bacterial isolates triggered false-positive Chlamydiazyme results. The cross-reactivity was particularly high for certain species: roughly one in five gonorrhea isolates and about 5% of E. coli isolates produced false positives.¹² Urinary tract infections were an especially troublesome source of contamination: in one study, 47% of E. coli UTIs and all tested Klebsiella pneumoniae UTIs produced false-positive Chlamydiazyme results on urine sediment.¹³

These older tests have largely been phased out in well-resourced settings, replaced by NAATs that detect chlamydia’s own genetic material rather than shared surface proteins. But enzyme immunoassay and rapid antigen tests are still used in some clinics, particularly in lower-resource settings and some point-of-care scenarios. If you received a positive result from a non-NAAT test, confirming with a NAAT is well worth doing.

Point-of-Care Tests vs. Lab-Based NAATs

The desire for same-day results has driven interest in rapid point-of-care chlamydia tests you can get results from during a single clinic visit. These fall into two broad categories: rapid antigen-based tests and rapid NAATs. The performance gap between them is large.

A systematic review of rapid point-of-care tests found that the best non-NAAT point-of-care test for chlamydia (the Chlamydia Rapid Test, or CRT) had pooled sensitivity around 80% for vaginal swabs and 77% for urine, with specificity around 99% for both.¹⁴ Another assessment estimated that if the CRT were used instead of a standard NAAT, for every 100 patients currently diagnosed, 10 to 35 cases would go undiagnosed and up to 191 false positives could occur. By contrast, a rapid NAAT like GeneXpert would miss only 1 to 3 cases and produce 0 to 2 false positives per 100 true diagnoses.¹⁵

If you are offered a rapid test at a clinic, it is worth asking what kind. A rapid NAAT performs comparably to a lab-sent NAAT. A rapid antigen test does not, and a negative result from one of those should not be the end of the story if you have symptoms or a known exposure.

Lab Contamination and Process Errors

Even a perfectly designed test can give a wrong result if something goes wrong between sample collection and analysis. An investigation at a women’s health clinic in Sweden traced unexpected positive chlamydia results back to RNA contamination present in the clinic environment itself. The contamination was causing samples to test positive before they ever reached the lab.¹⁶ This kind of contamination is thought to be rare, but it illustrates that a positive result can sometimes reflect something other than what is happening inside your body.

Mislabeled specimens, sample mix-ups, and processing errors are other mundane causes of wrong results. These are not unique to chlamydia testing; they can happen with any laboratory test. If a result does not match your clinical picture at all, requesting a repeat test on a freshly collected specimen is reasonable.

When Prevalence Changes What Your Result Means

There is a statistical reality that trips up many people (and some clinicians): even a very specific test produces more false positives when the condition being tested for is rare in the population. Imagine a test with 99.5% specificity used to screen 10,000 people. If 5% of them actually have chlamydia, the test would produce about 50 false negatives and roughly 48 false positives against 450 true positives — most positive results would be correct. But if only 0.5% of the population has chlamydia, you’d get about 50 true positives alongside roughly 50 false positives. Suddenly half of all positive results are wrong, even though the test has not changed.

This matters most in low-prevalence screening scenarios — for instance, screening populations with no symptoms and no known exposure. It is one reason some guidelines recommend confirmatory testing for positive results in low-prevalence settings. Researchers have found that confirmatory algorithms using a second NAAT can verify 89% to 99% of initial positive results, though the effectiveness depends on which combination of platforms is used.¹⁷ Some initial positives that fail to confirm on repeat testing can still be confirmed with more extensive testing, suggesting they were true infections with low bacterial loads rather than false positives.

Retesting and Repeat Infections

If you have been treated for chlamydia, the question of when and whether to retest involves balancing two competing risks: testing too early and getting a false positive from dead DNA, or not testing at all and missing a reinfection. Reinfection after treatment is genuinely common. Modeling data suggest that repeated positive tests peak between two and five months after treatment, and about 15% of people who retest after an initial positive result test positive again, compared with only 3% of those whose initial test was negative.¹⁸

In pregnancy, the stakes are higher. One study found chlamydia prevalence of about 18% among pregnant women screened, with nearly 4% having their only positive result on a second test later in pregnancy. Treatment failure or reinfection was documented in over 13% of those initially treated.¹⁹ This underscores why repeat testing during pregnancy is standard practice — a single negative early in pregnancy does not guarantee you remain uninfected.

The Emotional Weight of a Wrong Result

A chlamydia test result, whether right or wrong, lands in the middle of your relationships and your sense of yourself. Research on the psychosocial impact of chlamydia testing found that roughly a third of partners were upset upon learning of a positive result, and between 9% and 11% of tested individuals reported splitting with their partner afterward. Around 55% to 59% expressed nervousness about infertility, regardless of whether the infection had caused any damage.²⁰ A false positive can trigger all of that distress unnecessarily, while a false negative can allow an infection to go untreated and potentially be passed to partners or cause complications like pelvic inflammatory disease.

If you are dealing with a result that feels inconsistent with your situation — a positive when you have had no new partners, or persistent symptoms after a negative test — the most productive step is to get retested, ideally with a NAAT if you were not tested with one originally, and at all relevant body sites. One test result, especially from a rapid antigen test or taken at an awkward time relative to exposure or treatment, is not the final word.

Older Tests Still Floating Around

Chlamydia diagnostics have gone through several generations. Cell culture was once considered the gold standard but had sensitivity as low as 60-80% depending on the lab. Enzyme immunoassays like Chlamydiazyme improved access but introduced the cross-reactivity problems discussed earlier. Direct fluorescent antibody tests required skilled technicians and were labor-intensive. The arrival of NAATs in the 1990s transformed the field, and these remain the recommended first-line method today.¹

The reason this matters practically is that not all clinics have kept pace. If you are tested at a facility using an older methodology, the chance of both false positives and false negatives rises substantially. Even among NAATs, performance varies by platform. One comparison found that one NAAT platform (ProbeTec) had chlamydia sensitivity of about 83%, while two others (Combo2 and PCR) achieved 100%, on the same set of self-collected vaginal swabs.²¹ If your result does not align with your symptoms or risk profile, the specific test used is worth asking about.